News & Updates

A prospective cohort study has linked prenatal use of aspirin to better neurocognitive development in offspring.

Treatment with upadacitinib demonstrated superior efficacy in achieving near-complete skin clearance and little to no itch at 16 weeks compared with dupilumab among adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the LEVEL UP study presented at EADV 2024.

As-needed application of ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, resulted in long-term safety and disease control in children aged 2–11 years with mild-to-moderate atopic dermatitis (AD), according to updated results of the phase III TRuE-AD3 trial presented at EADV 2024.

The negative association between serum magnesium (Mg) levels and insulin resistance (IR) among schoolchildren is partly mediated by the BMI z-score, suggests a study in Mexico.

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Sacubitril/valsartan appears to be safe and beneficial in the treatment of children with heart failure (HF) attributable to systemic left ventricular systolic dysfunction (LVSD), with the drug having comparable efficacy as enalapril, according to the 52-week data from the phase 2/3 PANORAMA-HF* trial.

Some childhood cancer survivors (CCS) may experience psychological distress and have low health-related quality of life (HRQOL) after completing their cancer treatments, suggests a Singapore study.